litlas
Log inCreate account

Bernd Dörken

Active 1985–2018

140
Papers
27,531
Citations
100
h-index
140
i10-index

Citations

Citations per year for Bernd Dörken1960: 1 citations1986: 2 citations1987: 3 citations1988: 7 citations1989: 3 citations1990: 7 citations1991: 14 citations1992: 18 citations1993: 23 citations1994: 36 citations1995: 33 citations1996: 20 citations1997: 28 citations1998: 56 citations1999: 92 citations2000: 103 citations2001: 131 citations2002: 212 citations2003: 246 citations2004: 249 citations2005: 332 citations2006: 288 citations2007: 249 citations2008: 242 citations2009: 235 citations2010: 221 citations2011: 241 citations2012: 261 citations2013: 231 citations2014: 271 citations2015: 252 citations2016: 254 citations2017: 199 citations2018: 262 citations2019: 709 citations2020: 730 citations2021: 663 citations2022: 466 citations2023: 336 citations2024: 507 citations2025: 192 citations2026: 4 citations1961–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,888 citing papers, 27% of this breakdownGermany: 1,139 citing papers, 10.6% of this breakdownChina: 784 citing papers, 7.3% of this breakdownUnited Kingdom: 706 citing papers, 6.6% of this breakdownFrance: 520 citing papers, 4.8% of this breakdownItaly: 514 citing papers, 4.8% of this breakdownCanada: 403 citing papers, 3.8% of this breakdownJapan: 338 citing papers, 3.2% of this breakdownSpain: 291 citing papers, 2.7% of this breakdownNetherlands: 289 citing papers, 2.7% of this breakdownSwitzerland: 278 citing papers, 2.6% of this breakdownAustralia: 227 citing papers, 2.1% of this breakdown
0%27%Other 21.8%

Institutions

Fields

  • Medicine58.7%
  • Biochemistry, Genetics and Molecular Biology29.6%
  • Immunology and Microbiology6.7%
  • Materials Science1.4%
  • Agricultural and Biological Sciences1.2%
  • Engineering0.6%
  • Other1.8%

Topics

  • Lymphoma Diagnosis and Treatment5.1%
  • Telomeres, Telomerase, and Senescence3.3%
  • Immune Cell Function and Interaction2.3%
  • CAR-T cell therapy research2.2%
  • Cell death mechanisms and regulation2.2%
  • Chronic Lymphocytic Leukemia Research2.2%
  • Other82.7%

Coauthors

All papers

Open in search
  1. Senescence-associated reprogramming promotes cancer stemness

    Authors: Maja Milanovic, Dorothy Ngo-Yin Fan, Dimitri Belenki, J. Henry M. Däbritz, Zhen Zhao, Yong Yu, Jan R. Dörr, Lora Dimitrova, Dido Lenze, Inês Amorim Monteiro Barbosa, Marco Antonio Mendoza-Parra, Tamara Kanashova, Marlen Metzner, Katharina Pardon, Maurice Reimann, Andreas Trumpp, Bernd Dörken, Johannes Zuber, Hinrich Gronemeyer, Michael Hummel, Gunnar Dittmar, Soyoung Lee, Clemens A. Schmitt - Nature 2017 cited by 1,146

  2. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

    Authors: Jan R. Dörr, Yong Yu, Maja Milanovic, Gregor Beuster, Christin Zasada, J. Henry M. Däbritz, Jan Lisec, Dido Lenze, Anne Gerhardt, Katharina Schleicher, Susanne Kratzat, Bettina Purfürst, Stefan Walenta, Wolfgang Mueller‐Klieser, Markus H. Gräler, Michael Hummel, Ulrich Keller, Andreas K. Buck, Bernd Dörken, Lothar Willmitzer, Maurice Reimann, Stefan Kempa, Soyoung Lee, Clemens A. Schmitt - Nature 2013 cited by 539

  3. Oncogene-induced senescence as an initial barrier in lymphoma development

    Authors: Melanie Braig, Soyoung Lee, Christoph Loddenkemper, Cornelia Rudolph, Antoine H.F.M. Peters, Brigitte Schlegelberger, Harald Stein, Bernd Dörken, Thomas Jenuwein, Clemens A. Schmitt - Nature 2005 cited by 1,206

  4. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

    Authors: Marianne Sinn, Marcus Bahra, Torsten Liersch, Klaus Gellert, Helmut Messmann, Wolf O. Bechstein, Dirk Waldschmidt, Lutz Jacobasch, Martin Wilhelm, Bettina Rau, Robert Grützmann, Arndt Weinmann, Georg Maschmeyer, Uwe Pelzer, Jens Stieler, Jana K. Striefler, Michael Ghadimi, Sven Bischoff, Bernd Dörken, Helmut Oettle, Hanno Riess - Journal of Clinical Oncology 2017 cited by 296

  5. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes

    Authors: Anja Löffler, Peter Kufer, Ralf Lutterbüse, Florian Zettl, Peter T. Daniel, Jan M. Schwenkenbecher, Gert Riethmüller, Bernd Dörken, Ralf C. Bargou - Blood 2000 cited by 445

  6. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis

    Authors: Christopher Maximilian Arends, Joel Galan-Sousa, Kaja Hoyer, Willy Chan, Marten Jäger, Kenichi Yoshida, Ricarda Seemann, Daniel Noerenberg, Nils Waldhueter, Helga Fleischer-Notter, Friederike Christen, Clemens A. Schmitt, Bernd Dörken, Uwe Pelzer, Marianne Sinn, Tomasz Żemojtel, Seishi Ogawa, Sven Märdian, Adrian Schreiber, Annegret Kunitz, Ulrike Krüger, Lars Bullinger, Elena Mylonas, Mareike Frick, Frédérik Damm - Leukemia 2018 cited by 191

  7. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma

    Authors: Björn Lamprecht, Korden Walter, Stephan Kreher, Raman Kumar, Michael Hummel, Dido Lenze, Karl Köchert, Mohamed Amine Bouhlel, Julia Richter, Éric Soler, Ralph Stadhouders, Korinna Jöhrens, Kathrin D. Wurster, David F. Callen, Michael F. Harte, Maciej Giefing, Rachael Barlow, Harald Stein, Ioannis Anagnostopoulos, Martin Janz, Peter N. Cockerill, Reiner Siebert, Bernd Dörken, Constanze Bonifer, Stephan Mathas - Nature Medicine 2010 cited by 375

  8. Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

    Authors: Helmut Oettle, Hanno Riess, Jens Stieler, Gerhard Heil, Ingo Schwaner, Jörg Seraphin, Martin Görner, Matthias Mölle, Tim F. Greten, Volker Lakner, Sven Bischoff, Marianne Sinn, Bernd Dörken, Uwe Pelzer - Journal of Clinical Oncology 2014 cited by 484

  9. Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma

    Authors: Yong Yu, Kolja Schleich, Bin Yue, Sujuan Ji, Philipp Lohneis, Kristel Kemper, Mark R. Silvis, Nouar Qutob, Ellen van Rooijen, Melanie Werner‐Klein, Lianjie Li, Dhriti Dhawan, Svenja Meierjohann, Maurice Reimann, Abdel Elkahloun, Steffi Treitschke, Bernd Dörken, Christian Speck, Frédérick A. Mallette, Leonard I. Zon, Sheri L. Holmen, Daniel S. Peeper, Yardena Samuels, Clemens A. Schmitt, Soyoung Lee - Cancer Cell 2018 cited by 159

  10. Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

    Authors: Rami Rahal, Mareike Frick, Rodrigo Romero, Joshua M. Korn, Robert Kridel, Fong Chun Chan, Barbara Meissner, Hyo-Eun Carrie Bhang, Dave Ruddy, Audrey Kauffmann, Ali Farsidjani, Adnan Derti, Daniel P. Rakiec, Tara L. Naylor, Estelle Pfister, Steve G. Kovats, Sunkyu Kim, Kerstin Dietze, Bernd Dörken, Christian Steidl, Alexandar Tzankov, Michael Hummel, John E. Monahan, Michael Morrissey, Christine Fritsch, William R. Sellers, Vesselina G. Cooke, Randy D. Gascoyne, Georg Lenz, Frank Stegmeier - Nature Medicine 2013 cited by 332

  11. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

    Authors: Andreas Engert, Annette Plütschow, Hans Theodor Eich, Andreas Lohri, Bernd Dörken, Peter Borchmann, Bernhard Berger, Richard Greil, Kay Willborn, Martin Wilhelm, Jürgen Debus, Michael J. Eble, Martin Sökler, Antony D. Ho, Andreas Rank, Arnold Ganser, Lorenz Trümper, Carsten Bokemeyer, Hartmut Kirchner, Jörg Schubert, Zdeněk Král, Michael Fuchs, Hans–Konrad Müller–Hermelink, Rolf‐Peter Müller, Volker Diehl - New England Journal of Medicine 2010 cited by 921

  12. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

    Authors: Matthias Pfeifer, Bing Zheng, Tabea Erdmann, Hartmut Koeppen, Ronald McCord, Michael Grau, Annette M. Staiger, Akiko Chai, Thomas Sandmann, Hannelore Madle, Bernd Dörken, Y-W Chu, A I Chen, Dan I. Lebovic, Gilles Salles, M. S. Czuczman, Maria Corinna Palanca-Wessels, Oliver W. Press, Ranjana H. Advani, Franck Morschhauser, Bruce D. Cheson, Peter Lenz, German Ott, Andrew G. Polson, Kirsten Mundt, Georg Lenz - Leukemia 2015 cited by 152

  13. Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence

    Authors: Maurice Reimann, Soyoung Lee, Christoph Loddenkemper, Jan R. Dörr, Vedrana Tabor, Peter Aichele, Harald Stein, Bernd Dörken, Thomas Jenuwein, Clemens A. Schmitt - Cancer Cell 2010 cited by 179

  14. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

    Authors: Uwe Pelzer, Bernhard Opitz, G. Deutschinoff, Martina Stauch, P Reitzig, S. Hahnfeld, Lothar Müller, Martina Grunewald, Jens Stieler, Marianne Sinn, Timm Denecke, Sven Bischoff, Helmut Oettle, Bernd Dörken, Hanno Riess - Journal of Clinical Oncology 2015 cited by 266

  15. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Authors: Andreas Engert, Heinz Haverkamp, Carsten Kobe, Jana Marková, Christoph Renner, Antony D. Ho, Josée M. Zijlstra, Zdeněk Král, Michael Fuchs, Michael Hallek, Lothar Kanz, Hartmut Döhner, Bernd Dörken, Nicole Engel, Max S. Topp, Susanne Klutmann, Holger Amthauer, Andreas Bockisch, Regine Kluge, Clemens Kratochwil, Otmar Schober, Richard Greil, Reinhard Andreesen, Michael Kneba, Michael Pfreundschuh, Harald Stein, Hans Theodor Eich, Rolf‐Peter Müller, Markus Dietlein, Peter Borchmann, Volker Diehl - The Lancet 2012 cited by 632

  16. Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL

    Authors: Daniel Nagel, Stefani Spranger, Michelle Vincendeau, Michael Grau, Silke Raffegerst, Bernhard Kloo, Daniela Hlahla, Martin Neuenschwander, Jens Peter von Kries, Kamyar Hadian, Bernd Dörken, Peter Lenz, Georg Lenz, Dolores J. Schendel, Daniel Krappmann - Cancer Cell 2012 cited by 229

  17. Cellular senescence predicts treatment outcome in metastasised colorectal cancer

    Authors: Anja Haugstetter, Christoph Loddenkemper, Dido Lenze, Jörn Gröne, Christoph Standfuß, Iver Petersen, Bernd Dörken, Clemens A. Schmitt - British Journal of Cancer 2010 cited by 121

  18. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma

    Authors: Nikolai Schleußner, Olaf Merkel, Mariantonia Costanza, Huan-Chang Liang, Franziska Hummel, Chiara Romagnani, Pawel Durek, Ioannis Anagnostopoulos, Michael Hummel, Korinna Jöhrens, Antonia Niedobitek, Patrick R. Griffin, Roberto Piva, Henrike L. Sczakiel, Wilhelm Woessmann, Christine Damm‐Welk, Christian Hinze, Dagmar Stoiber, Bernhard Gillissen, Suzanne D. Turner, Eva Kaergel, Linda von Hoff, Michael Grau, Georg Lenz, Bernd Dörken, Claus Scheidereit, Lukas Kenner, Martin Janz, Stephan Mathas - Leukemia 2018 cited by 89

  19. Aberrantly expressed c‐Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF‐κB

    Authors: Stephan Mathas, Michael Hinz, Ioannis Anagnostopoulos, Daniel Krappmann, Andreas Lietz, Franziska Jundt, Kurt Bommert, Fatima Mechta‐Grigoriou, Harald Stein, Bernd Dörken, Claus Scheidereit - The EMBO Journal 2002 cited by 377

  20. Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

    Authors: Suzanne Lentzsch, Margarete Gries, Martin Janz, Ralf C. Bargou, Bernd Dörken, Markus Y. Mapara - Blood 2003 cited by 218

  21. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

    Authors: Uwe Pelzer, Ingo Schwaner, Jens Stieler, Mathias Adler, Jörg Seraphin, Bernd Dörken, Hanno Riess, Helmut Oettle - European Journal of Cancer 2011 cited by 380

  22. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

    Authors: Matthias Pfeifer, Michael Grau, Dido Lenze, Sören-Sebastian Wenzel, Annette Wolf, Brigitte Wollert‐Wulf, Kerstin Dietze, Hendrik Nogai, Benjamin Storek, Hannelore Madle, Bernd Dörken, Martin Janz, Stephan Dirnhofer, Peter Lenz, Michael Hummel, Alexandar Tzankov, Georg Lenz - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 262

  23. Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines

    Authors: Stephan Hailfinger, Hendrik Nogai, Christiane Pelzer, Maike Jaworski, Katrin Cabalzar, Jean-Enno Charton, Montserrat Guzzardi, Chantal Décaillet, Michael Grau, Bernd Dörken, Peter Lenz, Georg Lenz, Margot Thome - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 cited by 236

  24. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL

    Authors: Hendrik Nogai, Sören-Sebastian Wenzel, Stephan Hailfinger, Michael Grau, Eva Kaergel, Volkhard Seitz, Brigitte Wollert‐Wulf, Matthias Pfeifer, Annette Wolf, Mareike Frick, Kerstin Dietze, Hannelore Madle, Alexandar Tzankov, Michael Hummel, Bernd Dörken, Claus Scheidereit, Martin Janz, Peter Lenz, Margot Thome, Georg Lenz - Blood 2013 cited by 88